Video Reports – Melanoma Research Victoria https://melanomaresearchvic.com.au Tue, 22 Dec 2020 04:50:29 +0000 en-US hourly 1 https://melanomaresearchvic.com.au/wp-content/uploads/2017/12/cropped-favicon-32x32.png Video Reports – Melanoma Research Victoria https://melanomaresearchvic.com.au 32 32 Jason Luke, MD, FACP, on BRAF Mutations, Melanocytes and Melanoma Treatments https://melanomaresearchvic.com.au/jason-luke-md-facp-on-braf-mutations-melanocytes-and-melanoma-treatments-2 Wed, 30 Dec 2020 04:47:44 +0000 https://melanomaresearchvic.com.au/?p=16132 Jason Luke, MD, FACP of the UPMC Hillman Cancer Center spoke with CancerNetwork about the latest developments regarding melanocytes, dysregulated pathways and melanoma at the SMR Conference.

The post Jason Luke, MD, FACP, on BRAF Mutations, Melanocytes and Melanoma Treatments appeared first on Melanoma Research Victoria.

]]>
Source: cancer network, November 2020

Jason Luke, MD, FACP of the UPMC Hillman Cancer Center spoke with CancerNetwork about the latest developments regarding melanocytes, dysregulated pathways and melanoma at the SMR Conference.

Well it’s become quite clear from a number of elegant studies from people like Boris Bastian and Hunter Shane about the progression of melanocytes picking up serial dysregulated oncogenes and overexpression of certain pathways.

One of the surprising features about melanoma is that the BRAF that we target with BRAF-directed targeted therapies actually develops very early in melanocytes.

READ THE ORIGINAL FULL ARTICLE

The post Jason Luke, MD, FACP, on BRAF Mutations, Melanocytes and Melanoma Treatments appeared first on Melanoma Research Victoria.

]]>
Dr. Luke on the Importance of BRAF in Melanoma https://melanomaresearchvic.com.au/dr-luke-on-the-importance-of-braf-in-melanoma Tue, 01 Dec 2020 06:40:49 +0000 https://melanomaresearchvic.com.au/?p=16035 Jason J. Luke, MD, FACP, an associate professor of medicine in the Division of Hematology/Oncology and director of the Cancer Immunotherapeutics Center Immunology and Immunotherapy Program at the University of Pittsburgh Medical Center Hillman Cancer Center, discusses the importance of BRAF in melanoma.

The post Dr. Luke on the Importance of BRAF in Melanoma appeared first on Melanoma Research Victoria.

]]>
Source: OncLive, October 2020

Jason J. Luke, MD, FACP, an associate professor of medicine in the Division of Hematology/Oncology and director of the Cancer Immunotherapeutics Center Immunology and Immunotherapy Program at the University of Pittsburgh Medical Center Hillman Cancer Center, discusses the importance of BRAF in melanoma.

BRAF, found in half of all patients with melanoma, is a foundational mutation that was 1 of the seminal targets for early targeted agents, says Luke.

BRAF mutations also have to occur in conjunction with other mutations or dysregulations of the tumor.

READ THE ORIGINAL FULL ARTICLE

The post Dr. Luke on the Importance of BRAF in Melanoma appeared first on Melanoma Research Victoria.

]]>
Dr. Gibney on Selecting Between BRAF Inhibitor Regimens in Melanoma https://melanomaresearchvic.com.au/dr-gibney-on-selecting-between-braf-inhibitor-regimens-in-melanoma Fri, 27 Nov 2020 01:14:55 +0000 https://melanomaresearchvic.com.au/?p=16019 Geoffrey T. Gibney, MD, co-leader, Melanoma Disease Group and a member of the Developmental Therapeutics (Phase I) program at the Lombardi Comprehensive Cancer Center and MedStar Cancer Network, MedStar Georgetown University Hospital, discusses selecting between BRAF inhibitor regimens in melanoma.

The post Dr. Gibney on Selecting Between BRAF Inhibitor Regimens in Melanoma appeared first on Melanoma Research Victoria.

]]>
Source: OncLive, November 2020

Geoffrey T. Gibney, MD, co-leader, Melanoma Disease Group and a member of the Developmental Therapeutics (Phase I) program at the Lombardi Comprehensive Cancer Center and MedStar Cancer Network, MedStar Georgetown University Hospital, discusses selecting between BRAF inhibitor regimens in melanoma.

Patients with BRAF-mutant unresectable stage III or active stage IV melanoma can receive BRAF-targeted therapy or immunotherapy with anti–PD-L1 agents, Gibney explains.

If targeted therapy is selected, choosing between available BRAF inhibitor combinations can be challenging, says Gibney.

READ THE ORIGINAL FULL ARTICLE

The post Dr. Gibney on Selecting Between BRAF Inhibitor Regimens in Melanoma appeared first on Melanoma Research Victoria.

]]>
Dr. Luke on the Role of Targeted Therapy in Melanoma https://melanomaresearchvic.com.au/dr-luke-on-the-role-of-targeted-therapy-in-melanoma Thu, 26 Nov 2020 06:29:03 +0000 https://melanomaresearchvic.com.au/?p=16008 Jason J. Luke, MD, FACP, an associate professor of medicine in the Division of Hematology/Oncology and director of the Cancer Immunotherapeutics Center Immunology and Immunotherapy Program at the University of Pittsburgh Medical Center Hillman Cancer Center, discusses the role of targeted therapy in melanoma.

The post Dr. Luke on the Role of Targeted Therapy in Melanoma appeared first on Melanoma Research Victoria.

]]>
Source: OncLive, November 2020

Jason J. Luke, MD, FACP, an associate professor of medicine in the Division of Hematology/Oncology and director of the Cancer Immunotherapeutics Center Immunology and Immunotherapy Program at the University of Pittsburgh Medical Center Hillman Cancer Center, discusses the role of targeted therapy in melanoma.

Genomic profiling can help to inform the optimal treatment strategy for a patient with metastatic melanoma, Luke says.

BRAF mutations are present in about 50% of all patients with melanoma, Luke explains. Additionally, about 25% and 15% of patients harbor a RAS mutation and NF1 mutation, respectively. Patients with can also harbor KIT mutations, HER2 amplifications, or other rarer genetic aberrations, explains Luke.

READ THE ORIGINAL FULL ARTICLE

The post Dr. Luke on the Role of Targeted Therapy in Melanoma appeared first on Melanoma Research Victoria.

]]>
Dr. Garutti on the Potential Shift to Neoadjuvant Therapy in Melanoma https://melanomaresearchvic.com.au/dr-garutti-on-the-potential-shift-to-neoadjuvant-therapy-in-melanoma Mon, 26 Oct 2020 22:49:37 +0000 https://melanomaresearchvic.com.au/?p=15873 Mattia Garutti, MD, medical oncologist, Unit of Clinical Oncology, Centro di Riferimento Oncologico di Aviano, Aviano, Italy, discusses the potential shift to neoadjuvant therapy in melanoma.

The post Dr. Garutti on the Potential Shift to Neoadjuvant Therapy in Melanoma appeared first on Melanoma Research Victoria.

]]>
Source: OncLive, September 2020

Mattia Garutti, MD, medical oncologist, Unit of Clinical Oncology, Centro di Riferimento Oncologico di Aviano, Aviano, Italy, discusses the potential shift to neoadjuvant therapy in melanoma.

Patients with stage III melanoma have a high risk of relapse, says Garutti. As such, developing new therapies to increase the rates of cure among patients is a critical area of research.

Moreover, the potential shift from adjuvant therapy to neoadjuvant therapy may usher in a new era of melanoma management, Garutti explains.

READ THE ORIGINAL FULL ARTICLE

The post Dr. Garutti on the Potential Shift to Neoadjuvant Therapy in Melanoma appeared first on Melanoma Research Victoria.

]]>
Dr. Shoushtari on the Design of the CheckMate-067 Trial in Advanced Melanoma https://melanomaresearchvic.com.au/dr-shoushtari-on-the-design-of-the-checkmate-067-trial-in-advanced-melanoma Mon, 26 Oct 2020 06:43:53 +0000 https://melanomaresearchvic.com.au/?p=15866 Alexander N. Shoushtari, MD, an assistant attending physician at Memorial Sloan Kettering Cancer Center, discusses the design of the ?phase 3 CheckMate-067 trial in advanced melanoma.

The post Dr. Shoushtari on the Design of the CheckMate-067 Trial in Advanced Melanoma appeared first on Melanoma Research Victoria.

]]>
Source: OncLive, September 2020

Alexander N. Shoushtari, MD, an assistant attending physician at Memorial Sloan Kettering Cancer Center, discusses the design of the phase 3 CheckMate-067 trial in advanced melanoma.

The study randomized patients with previously untreated, unresectable, stage III or IV melanoma 1:1:1 to receive 1 mg/kg of nivolumab (Opdivo) plus 3 mg/kg of ipilimumab (Yervoy) for 4 doses, followed by 3 mg/kg of nivolumab; 3 mg/kg of nivolumab plus ipilimumab-matched placebo; or 3 mg/kg of ipilimumab for 4 doses plus nivolumab-matched placebo until progression or unacceptable toxicity, says Shoushtari.

Less common subtypes, such as mucosal and acral melanoma, were included in the study, but the majority of patients had cutaneous melanoma, adds Shoushtari. Notably, patients with uveal melanoma were excluded.

READ THE ORIGINAL FULL ARTICLE

The post Dr. Shoushtari on the Design of the CheckMate-067 Trial in Advanced Melanoma appeared first on Melanoma Research Victoria.

]]>
Dr. Eggermont on the Rationale for Evaluating Adjuvant Pembrolizumab in Advanced Melanoma https://melanomaresearchvic.com.au/dr-eggermont-on-the-rationale-for-evaluating-adjuvant-pembrolizumab-in-advanced-melanoma Thu, 22 Oct 2020 06:05:50 +0000 https://melanomaresearchvic.com.au/?p=15847 Alexander M. M. Eggermont, MD, PhD, professor of oncology, University of Paris-Sud, professor of oncological surgery, chair, International Research Network on Cancer, Erasmus University of Rotterdam, Joseph Maisin Honorary Chair of Oncological Surgery, Louvain Catholic University, discusses the rationale for the phase 3 EORTC 1325/KEYNOTE-054 trial, ?evaluating adjuvant pembrolizumab (Keytruda) versus placebo, in advanced melanoma.

The post Dr. Eggermont on the Rationale for Evaluating Adjuvant Pembrolizumab in Advanced Melanoma appeared first on Melanoma Research Victoria.

]]>
Source: OncLive, September 2020

Alexander M. M. Eggermont, MD, PhD, professor of oncology, University of Paris-Sud, professor of oncological surgery, chair, International Research Network on Cancer, Erasmus University of Rotterdam, Joseph Maisin Honorary Chair of Oncological Surgery, Louvain Catholic University, discusses the rationale for the phase 3 EORTC 1325/KEYNOTE-054 trial, evaluating adjuvant pembrolizumab (Keytruda) versus placebo, in advanced melanoma.

Early research showed response rates of about 45% to 50%, as well as 5-year overall survival rates of about 45%, with pembrolizumab (Keytruda) in treatment-naïve patients with advanced melanoma, says Eggermont.

As such, the phase 3 KEYNOTE-054 trial further evaluated pembrolizumab in the adjuvant setting versus placebo in patients with resected, high-risk, stage III melanoma, says Eggermont.

READ THE ORIGINAL FULL ARTICLE

The post Dr. Eggermont on the Rationale for Evaluating Adjuvant Pembrolizumab in Advanced Melanoma appeared first on Melanoma Research Victoria.

]]>
Dr. Glitza Olivia on the Potential Utility of Pembrolizumab/Selinexor in Advanced Melanoma https://melanomaresearchvic.com.au/dr-glitza-olivia-on-the-potential-utility-of-pembrolizumab-selinexor-in-advanced-melanoma Wed, 21 Oct 2020 06:19:22 +0000 https://melanomaresearchvic.com.au/?p=15834 Isabella C. Glitza Oliva, MD, PhD, MS, assistant professor, Department of Melanoma Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses ?the potential utility of pembrolizumab (Keytruda) in combination with selinexor ?(Xpovio) in advanced melanoma.

The post Dr. Glitza Olivia on the Potential Utility of Pembrolizumab/Selinexor in Advanced Melanoma appeared first on Melanoma Research Victoria.

]]>
Source: OncLive, October 2020

Isabella C. Glitza Oliva, MD, PhD, MS, assistant professor, Department of Melanoma Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the potential utility of pembrolizumab (Keytruda) in combination with selinexor (Xpovio) in advanced melanoma.

During the 2020 ESMO Virtual Congress, initial findings from a phase 1b study (NCT02419495) showed significant clinical activity in patients with metastatic melanoma.

Notably, no new safety signals were observed with the combination, which allowed the study to meet its primary objective of safety and tolerability, Glitza Olivia explains.

READ THE ORIGINAL FULL ARTICLE

 

The post Dr. Glitza Olivia on the Potential Utility of Pembrolizumab/Selinexor in Advanced Melanoma appeared first on Melanoma Research Victoria.

]]>
Adjuvant Nivolumab vs Ipilimumab https://melanomaresearchvic.com.au/adjuvant-nivolumab-vs-ipilimumab Tue, 20 Oct 2020 06:32:39 +0000 https://melanomaresearchvic.com.au/?p=15828 Jeffrey S. Weber, MD, PhD, of the Perlmutter Cancer Center, NYU Langone, discusses the 4-year recurrence-free and overall survival results from the CheckMate 238 study, which showed adjuvant nivolumab continues to be an effective treatment, vs the comparator ipilimumab, for patients with resected stage III/IV melanoma (Abstract 1076O).

The post Adjuvant Nivolumab vs Ipilimumab appeared first on Melanoma Research Victoria.

]]>
Source: The ASCO Post, ESMO Virtual Congress 2020

Jeffrey S. Weber, MD, PhD, of the Perlmutter Cancer Center, NYU Langone, discusses the 4-year recurrence-free and overall survival results from the CheckMate 238 study, which showed adjuvant nivolumab continues to be an effective treatment, vs the comparator ipilimumab, for patients with resected stage III/IV melanoma (Abstract 1076O).

READ THE ORIGINAL FULL ARTICLE

The post Adjuvant Nivolumab vs Ipilimumab appeared first on Melanoma Research Victoria.

]]>
Dr. Johnson on the Need for Novel Biomarkers in Melanoma https://melanomaresearchvic.com.au/dr-johnson-on-the-need-for-novel-biomarkers-in-melanoma Fri, 02 Oct 2020 06:27:08 +0000 https://melanomaresearchvic.com.au/?p=15721 Douglas B. Johnson, MD, MSCI, assistant professor of medicine, Vanderbilt University Medical Center, clinical director, Melanoma Research Program, Vanderbilt-Ingram Cancer Center, discusses the need to identify novel biomarkers in melanoma.

The post Dr. Johnson on the Need for Novel Biomarkers in Melanoma appeared first on Melanoma Research Victoria.

]]>
Source: OncLive, September 2020

Douglas B. Johnson, MD, MSCI, assistant professor of medicine, Vanderbilt University Medical Center, clinical director, Melanoma Research Program, Vanderbilt-Ingram Cancer Center, discusses the need to identify novel biomarkers in melanoma.

Although biomarkers such as BRAF mutations and PD-1/PD-L1 have assisted in treatment selection in the melanoma space, identifying additional biomarkers has been challenging, says Johnson.

In particular, it has been difficult to develop a biomarker that can inform when to use anti-PD-1 monotherapy, combination therapy, BRAF/MEK inhibition, or next-generation therapies such as intratumoral injections or tumor-infiltrating lymphocyte therapy.

READ THE ORIGINAL FULL ARTICLE

The post Dr. Johnson on the Need for Novel Biomarkers in Melanoma appeared first on Melanoma Research Victoria.

]]>